
Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Advertisement
Related to this article

Speakers at CHEST 2026 walked through the first CHEST guideline for non CF adult bronchiectasis, then took up the harder question it leaves open: which preventive therapy to start first.

On the opening day of CHEST 2026 in Phoenix, Arizona, the organization's flagship journal highlights a trio of key papers with practice-changing results.

Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.

Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.

SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Automated HCV Surveillance Shows Promise But Needs Validation
4
Income, Education NHL Mortality Gaps Widened in Canada in 2 Decades
5

